NCT01627587 - A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2011

Primary Completion Date

February 9, 2012

Study Completion Date

February 9, 2012

Conditions

Obstetric Labour, Premature

Interventions

DRUG

GSK221149 750 mg

Treatment A: 750 mg GSK221149 single dose

DRUG

Ketoconazole

Treatment B: 400 mg of Ketoconazole single dose

DRUG

GSK221149 100 mg

Treatment C: 100mg of GSK221149 single dose

DRUG

GSK221149 750 mg Fasted

Treatment D: 750 mg of GSK221149 administered fasted

DRUG

GSK221149 750 mg + Food

Treatment E: 750 mg of GSK221149 administered with a high fat meal

Trial Locations (1)

GSK Investigational Site, Austin